126 results
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
2 Aug 24
VBI Vaccines Provides an Update on its Restructuring Proceedings
4:05pm
”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
30 Jul 24
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
10:28am
of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
25 Jun 24
VBI Vaccines Announces Results of Annual General Meeting
4:15pm
in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
29 May 24
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
8:00am
”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
15 May 24
VBI Vaccines Reports First Quarter 2024 Financial Results
4:18pm
. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology and a proprietary mRNA
424B5
efd1q
15 May 24
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
afkz qpzmbko1myh
16 Apr 24
VBI Vaccines Reports Full Year 2023 Financial Results
8:00am
8-K
EX-99.1
7h4v2lco2xo0if5q
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
8-K
EX-99.2
wnoxmodunlldx3g4 bd3
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
424B5
2gqo jy13ff
11 Apr 24
Prospectus supplement for primary offering
9:06am
8-K
EX-99.1
0tqgeaz9e
3 Apr 24
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
8:00am
8-K
EX-99.1
7kf7cx 9u3dyveh9
2 Apr 24
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
8:00am
8-K
EX-99.1
gavzh lob892
14 Feb 24
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
8:34am
8-K
EX-99.1
pchqyba
20 Nov 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
wbhvghk
14 Nov 23
VBI Vaccines Reports Third Quarter 2023 Financial Results
4:07pm
8-K
EX-99.1
5mk12tqu1j55q0n6c
26 Oct 23
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
8:00am
8-K
EX-99.1
picjq
27 Sep 23
Regulation FD Disclosure
7:30am